KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition

• Published in: Leukemia 2023-04, Vol.37 (4), p.751-764
• Main Authors: Boila, Liberalis Debraj, Ghosh, Subhadeep, Bandyopadhyay, Subham K., Jin, Liqing, Murison, Alex, Zeng, Andy G. X., Shaikh, Wasim, Bhowmik, Satyaki, Muddineni, Siva Sai Naga Anurag, Biswas, Mayukh, Sinha, Sayantani, Chatterjee, Shankha Subhra, Mbong, Nathan, Gan, Olga I., Bose, Anwesha, Chakraborty, Sayan, Arruda, Andrea, Kennedy, James A., Mitchell, Amanda, Lechman, Eric R., Banerjee, Debasis, Milyavsky, Michael, Minden, Mark D., Dick, John E., Sengupta, Amitava
• Format: Article
• Language: English
• Subjects: 14; 14/19; 38; 38/23; 631/67/1059/602; 631/67/1990/283/1897; 64; 64/60; 96; 96/1; 96/31; Acute myeloid leukemia; Adenosine diphosphate; Apoptosis; Cancer Research; Chemoresistance; Corrosion resistance; Critical Care Medicine; Deoxyribonucleic acid; Deregulation; DNA; DNA damage; DNA demethylase; DNA repair; Epigenetics; Gene expression; Gene regulation; Genotoxicity; Hematology; Heterogeneity; Histone Demethylases - genetics; Histone Demethylases - metabolism; Histones; Humans; Immunological tolerance; Intensive; Internal Medicine; Jumonji Domain-Containing Histone Demethylases; Lethality; Leukemia; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - genetics; Leukemia, Myeloid, Acute - pathology; Lysine; Malignancy; Medicine; Medicine & Public Health; Mitochondria; Mutation; Oncology; Pathogenesis; Poly(ADP-ribose) polymerase; Poly(ADP-ribose) Polymerase Inhibitors - pharmacology; Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use; Proto-Oncogene Proteins c-bcl-2 - genetics; Ribose; Transcription activation; Xenotransplantation
• ISSN: 0887-6924; 1476-5551
• DOI: 10.1038/s41375-023-01833-z

Acute myeloid leukemia (AML) is a heterogeneous, aggressive malignancy with dismal prognosis and with limited availability of targeted therapies. Epigenetic deregulation contributes to AML pathogenesis. KDM6 proteins are histone-3-lysine-27-demethylases that play context-dependent roles in AML. We inform that KDM6-demethylase function critically regulates DNA-damage-repair-(DDR) gene expression in AML. Mechanistically, KDM6 expression is regulated by genotoxic stress, with deficiency of KDM6A-(UTX) and KDM6B-(JMJD3) impairing DDR transcriptional activation and compromising repair potential. Acquired KDM6A loss-of-function mutations are implicated in chemoresistance, although a significant percentage of relapsed-AML has upregulated KDM6A. Olaparib treatment reduced engraftment of KDM6A- mutant-AML-patient-derived xenografts, highlighting synthetic lethality using Poly-(ADP-ribose)-polymerase-(PARP)-inhibition. Crucially, a higher KDM6A expression is correlated with venetoclax tolerance. Loss of KDM6A increased mitochondrial activity, BCL2 expression, and sensitized AML cells to venetoclax. Additionally, BCL2A1 associates with venetoclax resistance, and KDM6A loss was accompanied with a downregulated BCL2A1. Corroborating these results, dual targeting of PARP and BCL2 was superior to PARP or BCL2 inhibitor monotherapy in inducing AML apoptosis, and primary AML cells carrying KDM6A- domain mutations were even more sensitive to the combination. Together, our study illustrates a mechanistic rationale in support of a novel combination therapy for AML based on subtype-heterogeneity, and establishes KDM6A as a molecular regulator for determining therapeutic efficacy.